Tom Williams/Vaccine
3 results
Coverage and timeliness of vaccination and the validity of routine estimates: Insights from a vaccine registry in Kenya.Adetifa IMO, Karia B, Mutuku A, Bwanaali T, Makumi A, Wafula J, Chome M, Mwatsuma P, Bauni E, Hammitt LL, Mataza C, Tabu C, Kamau T, Scott JAG
Vaccine, (2018). 36:7965-7974
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Mwangi TW
Vaccine, (2006). 24:4233-46
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Mwambingu G, Lowe B, Conway DJ
Vaccine, (2004). 23:718-28